Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine

Pueraria lobata (Willd.) Ohwi is a medicinal and edible homologous plant with a long history in China. Puerarin, the main component isolated from the root of Pueraria lobata, possesses a wide range of pharmacological properties. Daidzein and glucuronides are the main metabolites of puerarin and are...

Full description

Saved in:
Bibliographic Details
Main Author: Liang Zhang (Author)
Format: Book
Published: Taylor & Francis Group, 2019-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_e4dcb35d16a54bc0a92d86034905c337
042 |a dc 
100 1 0 |a Liang Zhang  |e author 
245 0 0 |a Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine 
260 |b Taylor & Francis Group,   |c 2019-01-01T00:00:00Z. 
500 |a 1071-7544 
500 |a 1521-0464 
500 |a 10.1080/10717544.2019.1660732 
520 |a Pueraria lobata (Willd.) Ohwi is a medicinal and edible homologous plant with a long history in China. Puerarin, the main component isolated from the root of Pueraria lobata, possesses a wide range of pharmacological properties. Daidzein and glucuronides are the main metabolites of puerarin and are excreted in the urine and feces. As active substrates of P-gp, multidrug resistance-associated protein and multiple metabolic enzymes, the pharmacokinetics of puerarin can be influenced by different pathological conditions and drug-drug interactions. Due to the poor water-solubility and liposolubility, the applications of puerarin are limited. So far, only puerarin injections and eye drops are on the market. Recent years, researches on improving the bioavailability of puerarin are developing rapidly, various nanotechnologies and preparation technologies including microemulsions and SMEDDS, dendrimers, nanoparticles and nanocrystals have been researched to improve the bioavailability of puerarin. In order to achieve biocompatibility and desired activity, more effective quality evaluations of nanocarriers are required. In this review, we summarize the pharmacokinetics and drug delivery systems of puerarin up to date. 
546 |a EN 
690 |a puerarin 
690 |a poorly soluble drug 
690 |a pharmacokinetics 
690 |a metabolites 
690 |a drug delivery systems 
690 |a microemulsions 
690 |a dendrimers 
690 |a nanoparticles 
690 |a nanocrystals 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Drug Delivery, Vol 26, Iss 1, Pp 860-869 (2019) 
787 0 |n http://dx.doi.org/10.1080/10717544.2019.1660732 
787 0 |n https://doaj.org/toc/1071-7544 
787 0 |n https://doaj.org/toc/1521-0464 
856 4 1 |u https://doaj.org/article/e4dcb35d16a54bc0a92d86034905c337  |z Connect to this object online.